Cargando…

Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE

OBJECTIVE: Anifrolumab is a fully human immunoglobulin G(1) κ monoclonal antibody specific for subunit 1 of the type I interferon (IFN) α receptor. In a phase IIb study of adults with moderate to severe SLE, anifrolumab treatment demonstrated substantial reductions in multiple clinical endpoints. He...

Descripción completa

Detalles Bibliográficos
Autores principales:	Casey, Kerry A, Guo, Xiang, Smith, Michael A, Wang, Shiliang, Sinibaldi, Dominic, Sanjuan, Miguel A, Wang, Liangwei, Illei, Gabor G, White, Wendy I
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2018
Materias:	Biomarker Studies
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6257383/ https://www.ncbi.nlm.nih.gov/pubmed/30538817 http://dx.doi.org/10.1136/lupus-2018-000286

Ejemplares similares

Correction: Type I interferon receptor blockade with anifrolumab corrects innate and adaptive immune perturbations of SLE
Publicado: (2018)

Anifrolumab, an Anti–Interferon‐α Receptor Monoclonal Antibody, in Moderate‐to‐Severe Systemic Lupus Erythematosus
por: Furie, Richard, et al.
Publicado: (2017)

Anifrolumab effects on rash and arthritis: impact of the type I interferon gene signature in the phase IIb MUSE study in patients with systemic lupus erythematosus
por: Merrill, Joan T, et al.
Publicado: (2018)

Long-term anifrolumab safe in SLE
por: McHugh, Jessica
Publicado: (2023)

Association of the interferon signature metric with serological disease manifestations but not global activity scores in multiple cohorts of patients with SLE
por: Kennedy, William P, et al.
Publicado: (2015)

Associations between circulating interferon and kynurenine/tryptophan pathway metabolites: support for a novel potential mechanism for cognitive dysfunction in SLE
por: Anderson, Erik W, et al.
Publicado: (2022)

Loss of antiphospholipid antibody positivity post-thrombosis in SLE
por: Khawaja, Muznay, et al.
Publicado: (2020)

Autoantibodies associated with systemic sclerosis in three autoimmune diseases imprinted by type I interferon gene dysregulation: a comparison across SLE, primary Sjögren’s syndrome and systemic sclerosis
por: Andraos, Rama, et al.
Publicado: (2022)

Novel immunoprofiling method for diagnosing SLE and evaluating therapeutic response
por: Lee, Jan-Mou, et al.
Publicado: (2022)

Erythrocyte-bound C4d in combination with complement and autoantibody status for the monitoring of SLE
por: Merrill, Joan T, et al.
Publicado: (2018)

Phenotypical changes and clinical significance of CD4(+)/CD8(+) T cells in SLE
por: Yuan, Shiwen, et al.
Publicado: (2022)

Safety profile of anifrolumab in patients with active SLE: an integrated analysis of phase II and III trials
por: Tummala, Raj, et al.
Publicado: (2021)

Platelet-bound C4d, low C3 and lupus anticoagulant associate with thrombosis in SLE
por: Petri, Michelle A, et al.
Publicado: (2019)

Osteopontin is associated with disease severity and antiphospholipid syndrome in well characterised Swedish cases of SLE
por: Wirestam, Lina, et al.
Publicado: (2017)

Comparison of PREDICTS atherosclerosis biomarker changes after initiation of new treatments in patients with SLE
por: McMahon, Maureen, et al.
Publicado: (2019)

Assessment of the independent associations of IgG, IgM and IgA isotypes of anticardiolipin with thrombosis in SLE
por: Domingues, Vinicius, et al.
Publicado: (2016)

Randomised prospective trial to assess the clinical utility of multianalyte assay panel with complement activation products for the diagnosis of SLE
por: Wallace, Daniel J, et al.
Publicado: (2019)

Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial
por: Bandyopadhyay, Somnath, et al.
Publicado: (2017)

Concordance and discordance in SLE clinical trial outcome measures: analysis of three anifrolumab phase 2/3 trials
por: Bruce, Ian N, et al.
Publicado: (2022)

Different indirect immunofluorescence ANA substrate performance in a diagnostic setting of patients with SLE and related disorders: retrospective review and analysis
por: Choi, May Y, et al.
Publicado: (2020)

SLE Plasma Profiling Identifies Unique Signatures of Lupus Nephritis and Discoid Lupus
por: Smith, Michael A., et al.
Publicado: (2019)

Effect of anti-P ribosomal and anti-NR2 antibodies on depression and cognitive processes in SLE: an integrated clinical and functional MRI study
por: Chessa, Elisabetta, et al.
Publicado: (2023)

Plasma-based microsatellite instability detection strategy to guide immune checkpoint blockade treatment
por: Wang, Zhenghang, et al.
Publicado: (2020)

PRKDC: new biomarker and drug target for checkpoint blockade immunotherapy
por: Tan, Kien Thiam, et al.
Publicado: (2020)

Characterisation of anifrolumab, a fully human anti-interferon receptor antagonist antibody for the treatment of systemic lupus erythematosus
por: Riggs, Jeffrey M, et al.
Publicado: (2018)

Clinical Pharmacokinetics, Pharmacodynamics, and Immunogenicity of Anifrolumab
por: Tang, Weifeng, et al.
Publicado: (2023)

Multiparametric MRI of early tumor response to immune checkpoint blockade in metastatic melanoma
por: Lau, Doreen, et al.
Publicado: (2021)

Anifrolumab efficacy and safety by type I interferon gene signature and clinical subgroups in patients with SLE: post hoc analysis of pooled data from two phase III trials
por: Vital, Edward M, et al.
Publicado: (2022)

Anxiety and depression severity in neuropsychiatric SLE are associated with perfusion and functional connectivity changes of the frontolimbic neural circuit: a resting-state f(unctional) MRI study
por: Antypa, Despina, et al.
Publicado: (2021)

Clinical implications of discordance between anti-dsDNA antibodies by multiplex flow immunoassay and Crithidia luciliae assay in a multiethnic racial cohort of patients with SLE
por: Zaminski, Devyn, et al.
Publicado: (2023)

Interferon Inhibition for Lupus with Anifrolumab: Critical Appraisal of the Evidence Leading to FDA Approval
por: Loncharich, Michael F., et al.
Publicado: (2022)

Tumor copy-number alterations predict response to immune-checkpoint-blockade in gastrointestinal cancer
por: Lu, Zhihao, et al.
Publicado: (2020)

BAFF (B cell activating factor) transcript level in peripheral blood of patients with SLE is associated with same-day disease activity as well as global activity over the next year
por: Zollars, Eric, et al.
Publicado: (2015)

Erythrocyte complement receptor 1 (ECR1) and erythrocyte-bound C4d (EC4d) in the prediction of poor pregnancy outcomes in systemic lupus erythematosus (SLE)
por: Conklin, John, et al.
Publicado: (2022)

Lupus Low Disease Activity State (LLDAS) attainment discriminates responders in a systemic lupus erythematosus trial: post-hoc analysis of the Phase IIb MUSE trial of anifrolumab
por: Morand, Eric F, et al.
Publicado: (2018)

Combination therapy with T cell engager and PD-L1 blockade enhances the antitumor potency of T cells as predicted by a QSP model
por: Ma, Huilin, et al.
Publicado: (2020)

Tumor mutation burden for predicting immune checkpoint blockade response: the more, the better
por: Zheng, Ming
Publicado: (2022)

Intratumoral CD103+ CD8+ T cells predict response to PD-L1 blockade
por: Banchereau, Romain, et al.
Publicado: (2021)

Anifrolumab for systemic lupus erythematosus
Publicado: (2022)

Molecular basis for antagonistic activity of anifrolumab, an anti-interferon–α receptor 1 antibody
por: Peng, Li, et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_hfu8f5lh1creaudoa93abspipi